(Q38758381)

6 September 2017

0 references

Combination therapy versus monotherapy for pulmonary arterial hypertension: a meta-analysis (English)

1 reference

6 September 2017

arterial hypertension

1 reference

1 reference

8

Steeve Provencher

1 reference

6 September 2017

3

Jean-Christophe Lega

1 reference

6 September 2017

4

Yves Lacasse

1 reference

6 September 2017

Annie Christine Lajoie

1

1 reference

6 September 2017

Gabriel Lauzière

2

1 reference

6 September 2017

Sylvie Martin

5

1 reference

6 September 2017

Serge Simard

6

1 reference

6 September 2017

Sebastien Bonnet

7

1 reference

6 September 2017

26 February 2016

1 reference

The Lancet. Respiratory medicine

6 September 2017

1 reference

6 September 2017

4

1 reference

6 September 2017

4

1 reference

6 September 2017

291-305

1 reference

Updated Clinical Classification of Pulmonary Hypertension

6 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2900027-8

7 January 2021

2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2900027-8

7 January 2021

Treatment of pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2900027-8

7 January 2021

Updated treatment algorithm of pulmonary arterial hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2900027-8

7 January 2021

Updated evidence-based treatment algorithm in pulmonary arterial hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2900027-8

7 January 2021

A meta-analysis of randomized controlled trials in pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2900027-8

7 January 2021

Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2900027-8

7 January 2021

Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2900027-8

7 January 2021

Meta-analysis of monotherapy versus combination therapy for pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2900027-8

7 January 2021

Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2900027-8

7 January 2021

Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2900027-8

7 January 2021

Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2900027-8

7 January 2021

Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2900027-8

7 January 2021

Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2900027-8

7 January 2021

Tadalafil therapy for pulmonary arterial hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2900027-8

7 January 2021

Validation of 6-minute walk distance as a surrogate end point in pulmonary arterial hypertension trials

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2900027-8

7 January 2021

Do Changes of 6-Minute Walk Distance Predict Clinical Events in Patients With Pulmonary Arterial Hypertension?

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2900027-8

7 January 2021

Baseline and follow-up 6-min walk distance and brain natriuretic peptide predict 2-year mortality in pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2900027-8

7 January 2021

Methodologic guidelines for systematic reviews of randomized control trials in health care from the Potsdam Consultation on Meta-Analysis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2900027-8

7 January 2021

Clinical biostatistics. LIV. The biostatistics of concordance

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2900027-8

7 January 2021

The Cochrane Collaboration's tool for assessing risk of bias in randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2900027-8

7 January 2021

End points and clinical trial design in pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2900027-8

7 January 2021

Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2900027-8

7 January 2021

Random-effects meta-analyses are not always conservative.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2900027-8

7 January 2021

Publication bias: a brief review for clinicians

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2900027-8

7 January 2021

Bias in meta-analysis detected by a simple, graphical test

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2900027-8

7 January 2021

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2900027-8

7 January 2021

Riociguat for the treatment of pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2900027-8

7 January 2021

Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2900027-8

7 January 2021

Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2900027-8

7 January 2021

Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2900027-8

7 January 2021

Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: a randomized, placebo-controlled, double-blinded trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2900027-8

7 January 2021

Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2900027-8

7 January 2021

Macitentan and morbidity and mortality in pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2900027-8

7 January 2021

Selexipag for the Treatment of Pulmonary Arterial Hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2900027-8

7 January 2021

Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2900027-8

7 January 2021

Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2900027-8

7 January 2021

Randomized study of adding tadalafil to existing ambrisentan in pulmonary arterial hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2900027-8

7 January 2021

Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2900027-8

7 January 2021

Effect of macitentan on hospitalizations: results from the SERAPHIN trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2900027-8

7 January 2021

Evaluation of the predictive value of a clinical worsening definition using 2-year outcomes in patients with pulmonary arterial hypertension: a REVEAL Registry analysis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2900027-8

7 January 2021

Effect of pulmonary arterial hypertension-specific therapies on health-related quality of life: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2900027-8

7 January 2021

Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL).

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2900027-8

7 January 2021

Predicting outcomes in pulmonary arterial hypertension based on the 6-minute walk distance

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2900027-8

7 January 2021

10.1016/S2213-2600(16)00027-8

Identifiers

DOI

1 reference

6 September 2017

1 reference